Clinical trials: Breast Cancer, Male
Localized Breast Cancer, Localized Prostate Cancer
Use of Organic Germanium or Placebo for the Prevention of Radiation Induced Fatigue
Participants will be diagnosed with localized prostate or breast cancer and be scheduled to undergo external beam radiation therapy.
- Conditions
- Localized Breast Cancer, Localized Prostate Cancer, Patients Receiving External Beam Radiotherapy
- Trial name
- NCT00651417
- Testing
- Organic Germanium
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Arizona Oncology Services
Breast Cancer, Colorectal Cancer
Physical Training and Cancer-a Multicenter Clinical Trial
Excessive tiredness (fatigue) is a common problem in cancer patients and can affect quality of life negatively. There is limited knowledge about the physical mechanisms that cause fatigue, and there is no medical treatment.
- Conditions
- Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- Phys-Can (NCT02473003)
- Testing
- high intensity exercise, low/medium intensity exercise, Behavioral medicine strategies
- Volunteers
- 600 people
- Sponsor
- Uppsala University
Breast Cancer
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- NCT00362973
- Testing
- laboratory biomarker analysis, needle biopsy, positron emission tomography
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- University of Washington
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Prostatic Neoplasm, Survivorship
Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
Frailty is one of the main reasons older adults lose independence. Frailty describes a reduced ability to withstand stress on the physiological scale, or a reduced physiological reserve.
- Conditions
- Prostatic Neoplasm, Survivorship, Frailty, Aging
- Trial name
- ADRIAN (NCT05968144)
- Testing
- Dietary recommendations, Time-restricted eating
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT07259304
- Testing
- Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
- Where
- 3 sites in United States
- Volunteers
- 173 people
- Sponsor
- University of Southern California
Advanced or Metastatic Solid Tumors, Breast Cancer
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- NCT05787587
- Testing
- IDE-161, Pembrolizumab
- Where
- 27 sites in United States
- Volunteers
- 216 people
- Sponsor
- IDEAYA Biosciences
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01394211
- Testing
- anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Breast Cancer, Healthy Volunteer
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
Background: Blister fluid contains many of the same biomarkers (substances that can be used to determine the effects of certain kinds of treatments) as blood and urine samples, particularly regarding changes in the skin.
- Conditions
- Breast Cancer, Healthy Volunteer, Prostate Cancer
- Trial name
- NCT00923104
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Breast Neoplasms, Ovarian Neoplasms
Massage Therapy for Cancer-Related Fatigue
The purpose of this study is to develop methods for studying the effect of bodywork therapy on symptoms of fatigue in patients undergoing cancer chemotherapy.
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT00039793
- Testing
- Moderate-intensity and low-intensity bodywork therapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Cancer, Breast Cancer
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Add-Aspirin aims to assess whether regular aspirin use after standard curative therapy can prevent recurrence and improve survival in individuals with non-metastatic common tumours.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02804815
- Testing
- Aspirin 100mg, Aspirin 300mg
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 11,000 people
- Sponsor
- University College, London
Breast Carcinoma, Prostate Cancer Surgery
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease.
- Conditions
- Breast Carcinoma, Prostate Cancer Surgery, Thyroid Cancer, Parathyroid Adenomas
- Trial name
- NCT06835426
- Testing
- Single intravenous injection of the radiotracer, Imaging resected specimen using the high-resolution PET-CT specimen imager
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Algemeen Ziekenhuis Maria Middelares
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Breast Cancer, Lung Cancer
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Background: Paclitaxel is a chemotherapy drug that is commonly used to treat different types of cancers. However, cancer tumors can become resistant to paclitaxel, and as a result they will fail to accumulate sufficient…
- Conditions
- Breast Cancer, Lung Cancer, Renal Cancer, Adrenal Cancer
- Trial name
- NCT01086696
- Testing
- FPAC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Prostate Cancer
Precise Oncology Interventions in Nutrition and Training (OnPoint)
The purpose of this study is to see if survivors of breast, prostate, colorectal or lymphoma cancer who receive a personal referral to a targeted nutrition and exercise program will be able to eat a healthier diet and be more…
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma
- Trial name
- OnPoint (NCT06534918)
- Testing
- Fitbit, Nutrition Course: Group Sessions, Physical Activity Program: Group Sessions
- Where
- United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- University of Miami
Breast Cancer, Prostate Cancer
Physical Activities by Technology Help (PATH)
PATH is a research study for cancer survivors to help participants to become more active. Studies suggested an association between inactivity and cancer.
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- PATH (NCT03212079)
- Testing
- Mycoach Smart Text, MyCoach on Amazon Alexa
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Johns Hopkins University
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Breast Cancer, Lung Cancer
Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients
This is a randomized parallel group trial designed to evaluate the impact of implementing geriatrician-prescribed interventions based on the comprehensive geriatric assessment (CGA), on the ability to deliver adequate…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
- Trial name
- GIVE (NCT02785887)
- Testing
- Geriatrician review
- Where
- 3 sites in Italy
- Volunteers
- 233 people
- Sponsor
- Azienda USL 4 Prato
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.